Biotech company NeuroScientific Biopharmaceuticals is on the cutting-edge of developing pharmaceutical solutions for neurological disorders and is dedicated to world-class science that improve patient’s lives. The company’s CEO and MD Matt Liddelow sat down with TechInvest recently on the sidelines of the TechKnow Invest Roadshow in Sydney to talk about what the company does, history of the technology and reasoning behind an upcoming IPO and ASX-listing.